Total Payments
$1.1M
2024 Payments
$127,585
Companies
25
Transactions
857
Payment Breakdown by Category
Other$562,519 (50.4%)
Consulting$426,477 (38.2%)
Travel$98,412 (8.8%)
Food & Beverage$16,290 (1.5%)
Research$11,975 (1.1%)
Education$117.60 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $426,477 | 73 | 38.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $424,779 | 132 | 38.1% |
| Compensation for serving as faculty or as a speaker for a medical education program | $122,740 | 41 | 11.0% |
| Travel and Lodging | $98,412 | 378 | 8.8% |
| Food and Beverage | $16,290 | 218 | 1.5% |
| Grant | $15,000 | 2 | 1.3% |
| Unspecified | $11,975 | 11 | 1.1% |
| Education | $117.60 | 2 | 0.0% |
Payments by Type
General
$1.1M
846 transactions
Research
$11,975
11 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| JAZZ PHARMACEUTICALS INC. | $333,454 | 302 | $0 (2024) |
| SERVIER PHARMACEUTICALS LLC | $167,773 | 224 | $0 (2023) |
| Kite Pharma, Inc. | $156,188 | 25 | $0 (2024) |
| Amgen Inc. | $128,775 | 121 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $63,450 | 6 | $0 (2022) |
| GENZYME CORPORATION | $55,963 | 25 | $0 (2023) |
| SOBI, INC | $48,628 | 69 | $0 (2024) |
| PFIZER INC. | $36,756 | 7 | $0 (2024) |
| Celularity Inc. | $15,069 | 3 | $0 (2022) |
| Gilead Sciences, Inc. | $13,375 | 3 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $127,585 | 99 | JAZZ PHARMACEUTICALS INC. ($63,107) |
| 2023 | $170,349 | 108 | JAZZ PHARMACEUTICALS INC. ($101,534) |
| 2022 | $289,397 | 297 | SERVIER PHARMACEUTICALS LLC ($137,919) |
| 2021 | $137,840 | 78 | Amgen Inc. ($51,109) |
| 2020 | $156,210 | 87 | Amgen Inc. ($57,337) |
| 2019 | $90,338 | 66 | Kite Pharma, Inc. ($39,563) |
| 2018 | $66,847 | 51 | Jazz Pharmaceuticals Inc. ($31,580) |
| 2017 | $77,224 | 71 | Jazz Pharmaceuticals Inc. ($45,640) |
All Payment Transactions
857 individual payment records from CMS Open Payments — Page 1 of 35
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | PFIZER INC. | ELIQUIS (Drug) | Consulting Fee | Cash or cash equivalent | $11,340.00 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 12/18/2024 | JAZZ PHARMACEUTICALS INC. | RYLAZE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,460.00 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/18/2024 | JAZZ PHARMACEUTICALS INC. | RYLAZE (Drug) | Travel and Lodging | In-kind items and services | $17.42 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/12/2024 | SOBI, INC | GAMIFANT (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,860.00 | General |
| Category: HEMATOLOGY | ||||||
| 12/12/2024 | SOBI, INC | GAMIFANT (Drug) | Travel and Lodging | Cash or cash equivalent | $803.37 | General |
| Category: HEMATOLOGY | ||||||
| 12/12/2024 | SOBI, INC | GAMIFANT (Drug) | Food and Beverage | In-kind items and services | $123.96 | General |
| Category: HEMATOLOGY | ||||||
| 12/12/2024 | JAZZ PHARMACEUTICALS INC. | RYLAZE (Drug) | Food and Beverage | In-kind items and services | $121.84 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/06/2024 | JAZZ PHARMACEUTICALS INC. | RYLAZE (Drug) | Food and Beverage | In-kind items and services | $143.43 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/06/2024 | ABBVIE INC. | EPKINLY (Drug) | — | In-kind items and services | $25.00 | Research |
| Study: A Phase 3, Multicenter, Randomized, Open-Label Study of Epcoritamab Plus Lenalidomide Compared to Rituximab Plus Gemcitabine and Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma • Category: ONCOLOGY | ||||||
| 11/19/2024 | Kite Pharma, Inc. | — | Consulting Fee | Cash or cash equivalent | $7,125.00 | General |
| 11/13/2024 | JAZZ PHARMACEUTICALS INC. | RYLAZE (Drug) | Travel and Lodging | In-kind items and services | $402.58 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 11/05/2024 | JAZZ PHARMACEUTICALS INC. | RYLAZE (Drug) | Travel and Lodging | In-kind items and services | $18.99 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 11/05/2024 | JAZZ PHARMACEUTICALS INC. | RYLAZE (Drug) | Food and Beverage | In-kind items and services | $7.50 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 10/31/2024 | JAZZ PHARMACEUTICALS INC. | RYLAZE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $7,020.00 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 10/26/2024 | JAZZ PHARMACEUTICALS INC. | RYLAZE (Drug) | Travel and Lodging | In-kind items and services | $500.80 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 10/26/2024 | JAZZ PHARMACEUTICALS INC. | RYLAZE (Drug) | Travel and Lodging | In-kind items and services | $288.85 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 10/26/2024 | JAZZ PHARMACEUTICALS INC. | RYLAZE (Drug) | Travel and Lodging | In-kind items and services | $288.85 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 10/24/2024 | JAZZ PHARMACEUTICALS INC. | RYLAZE (Drug) | Travel and Lodging | In-kind items and services | $150.65 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 10/24/2024 | JAZZ PHARMACEUTICALS INC. | RYLAZE (Drug) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 10/22/2024 | JAZZ PHARMACEUTICALS INC. | RYLAZE (Drug) | Travel and Lodging | In-kind items and services | $392.12 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 10/22/2024 | JAZZ PHARMACEUTICALS INC. | RYLAZE (Drug) | Travel and Lodging | In-kind items and services | $112.20 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 10/22/2024 | JAZZ PHARMACEUTICALS INC. | RYLAZE (Drug) | Food and Beverage | In-kind items and services | $46.49 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 10/22/2024 | JAZZ PHARMACEUTICALS INC. | RYLAZE (Drug) | Food and Beverage | In-kind items and services | $6.01 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 10/17/2024 | JAZZ PHARMACEUTICALS INC. | RYLAZE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $7,020.00 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 10/14/2024 | JAZZ PHARMACEUTICALS INC. | RYLAZE (Drug) | Travel and Lodging | In-kind items and services | $335.13 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab | ABBVIE INC. | $11,828 | 9 |
| PCYC-1140-IM | Pharmacyclics LLC, An AbbVie Company | $121.84 | 1 |
| A Phase 3, Multicenter, Randomized, Open-Label Study of Epcoritamab Plus Lenalidomide Compared to Rituximab Plus Gemcitabine and Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | ABBVIE INC. | $25.00 | 1 |
About Dr. Mitchell Cairo, MD
Dr. Mitchell Cairo, MD is a Pediatric Hematology-Oncology healthcare provider based in Hawthorne, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/17/2006. The National Provider Identifier (NPI) number assigned to this provider is 1669446399.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mitchell Cairo, MD has received a total of $1.1M in payments from pharmaceutical and medical device companies, with $127,585 received in 2024. These payments were reported across 857 transactions from 25 companies. The most common payment nature is "Consulting Fee" ($426,477).
Ad
Practice Information
- Specialty Pediatric Hematology-Oncology
- Location Hawthorne, NY
- Active Since 02/17/2006
- Last Updated 01/12/2015
- Taxonomy Code 2080P0207X
- Entity Type Individual
- NPI Number 1669446399
Products in Payments
- DEFITELIO (Drug) $200,324
- Blincyto (Biological) $128,775
- ASPARLAS (Drug) $122,572
- Yescarta (Drug) $75,563
- RYLAZE (Drug) $55,888
- ELIQUIS (Drug) $50,256
- Defitelio (Drug) $48,591
- ELITEK (Biological) $40,083
- GAMIFANT (Drug) $33,685
- Erwinaze (Drug) $25,297
- Asparlas (Drug) $18,382
- Gamifant (Drug) $14,943
- Narsoplimab (Drug) $12,375
- EPKINLY (Drug) $10,825
- COSENTYX (Biological) $10,248
- Non-Covered $6,858
- NO PRODUCT DISCUSSED (Drug) $6,000
- Imbruvica (Drug) $4,456
- ONCASPAR (Drug) $3,665
- GIAPREZA (Drug) $2,100
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pediatric Hematology-Oncology Doctors in Hawthorne
Claudio Sandoval, Md, MD
Pediatric Hematology-Oncology — Payments: $246,267
Pediatric Hematology-Oncology $246,267
Oya Tugal, Md, MD
Pediatric Hematology-Oncology — Payments: $53,147
Pediatric Hematology-Oncology $53,147
Mehmet Ozkaynak, Md, MD
Pediatric Hematology-Oncology — Payments: $1,947
Pediatric Hematology-Oncology $1,947
Edo Schaefer, Md, MD
Pediatric Hematology-Oncology — Payments: $1,400
Pediatric Hematology-Oncology $1,400
Dr. Andrew Bellantoni, Md, MD
Pediatric Hematology-Oncology — Payments: $1,060
Pediatric Hematology-Oncology $1,060
Dr. Allyson Flower, M.d, M.D
Pediatric Hematology-Oncology — Payments: $423.32
Pediatric Hematology-Oncology $423.32